Safety
-
Singulair (montelukast sodium) tablets, chewable tables and oral granules January 2009
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2009
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. |
ADVERSE REACTIONS
- Post-Marketing Experience
- epistaxis added
PATIENT PACKAGE INSERT
- Less Common Side Effects
- nosebleed, palpitations
-
-







